Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
platelet lysate (Regenexx)
- Development stage
- Unknown
- Lead developer
- Regenexx
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Epidural
01
Overview
Platelet lysate (PL) is an autologous biologic therapy developed by Regenexx, LLC, specifically for the treatment of lumbosacral radiculopathy (sciatica). It is an advanced derivative of platelet-rich plasma (PRP) produced by lysing (breaking open) the patient's own platelets to immediately release a high concentration of growth factors, cytokines, and exosomes. Unlike standard PRP, which contains intact platelets that release factors over time, PL provides an immediate anti-inflammatory effect, making it more suitable for use around sensitive nerve roots in the epidural space. The treatment is administered via image-guided epidural injection and is being evaluated as a regenerative alternative to corticosteroid injections.
- Brand names
- Regenexx-PL
- Other names
- PLautologous platelet lysateRegenexx Platelet Lysate
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)IGF-1R (Insulin-like growth factor 1 receptor)FGFR (Fibroblast growth factor receptor)PDGFRA (Platelet-derived growth factor receptor alpha)EGFR T790M (Epidermal growth factor receptor T790M mutant)TGFBR1
Beyond the preview
Go deeper on platelet lysate (Regenexx).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on platelet lysate (Regenexx).